Nephrology · Obstetrics & Gynecology ·
Review outlines reproductive care in monogenic kidney disease
A clinical review discusses reproductive health and pregnancy counseling for people with ADPKD, Alport spectrum disorders, Fabry disease, and monogenic podocytopathies. It emphasizes kidney function and comorbidities in risk assessment, coordinated care, and the limits of the largely retrospective evidence.
- Pregnancy risks track kidney function and comorbidities.
- Counseling includes inheritance and reproductive options.
- Coordinated care spans preconception through postpartum.
- Evidence is largely retrospective and limited.
The review addresses reproductive care beyond pregnancy for people with monogenic kidney diseases, using autosomal dominant polycystic kidney disease (ADPKD), Alport spectrum disorders, Fabry disease, and monogenic podocytopathies presenting as focal segmental glomerulosclerosis as examples. It covers fertility, contraception, inheritance counseling, assisted reproduction, pregnancy, and postpartum care; it is not a clinical trial and reports no sample size.
The authors state that adverse maternal and fetal outcomes are driven mainly by reduced kidney function, chronic hypertension, proteinuria, prior preeclampsia, and major extrarenal disease. They outline preconception risk assessment, planned discontinuation or transition of potentially fetotoxic medicines, and genetic counseling about recurrence risk and reproductive options, including prenatal diagnosis and preimplantation genetic testing. During pregnancy, they describe coordinated nephrology, maternal–fetal medicine, and genetics care, with blood pressure and kidney monitoring and attention to disease-specific complications.
The review also highlights postpartum medication review, breastfeeding counseling, and ongoing kidney and cardiovascular surveillance. Its guidance should be interpreted in light of limited evidence: data are largely retrospective and may overrepresent milder disease, with important gaps in fertility outcomes, male reproductive health, newer targeted therapies, and genotype-specific pregnancy risks. The source is identified as publish-ahead-of-print dated November 6, 2026; that date warrants verification.
In practice
For people with ADPKD, Alport spectrum disorders, Fabry disease, or monogenic podocytopathies who are considering pregnancy, the review supports individualized preconception assessment that considers kidney function, hypertension, proteinuria, prior preeclampsia, and extrarenal disease, alongside medication planning and genetic counseling. It describes coordinated nephrology and maternal–fetal medicine care during pregnancy and follow-up after delivery. This is review-based guidance, not trial evidence or a formal guideline; available data are limited, largely retrospective, and do not resolve risks for all genotypes or newer therapies.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Clinical Journal of the American Society of Nephrology: Reproductive Health in Monogenic Kidney Disease ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.